Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in adults with sickle cell disease
2024-515569-32-00Phase 2Authorised
- Sponsor
- Julius Clinical
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitapivat in sickle cell disease (SCD), sponsored by Julius Clinical. Primary endpoints: Safety of mitapivat, Change in sickling behavior and 1 more. Planned start Aug 2024; status: authorised.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-515569-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515569-32-00.